Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Imprint of unconventional T-cell response in acute hepatitis C persists despite successful early antiviral treatment.
Du Y, Khera T, Strunz B, Deterding K, Todt D, Woller N, Engelskircher SA, Hardtke S, Port K, Ponzetta A, Steinmann E, Cornberg M, Hengst J, Björkström NK, Wedemeyer H; HepNet Acute HCV Ⅳ Study Group. Du Y, et al. Among authors: hardtke s. Eur J Immunol. 2022 Mar;52(3):472-483. doi: 10.1002/eji.202149457. Epub 2021 Dec 13. Eur J Immunol. 2022. PMID: 34843107 Free article.
[Paradigmatic change in treatment of viral hepatitides].
Wedemeyer H, Hardtke S, Manns MP, Cornberg M. Wedemeyer H, et al. Among authors: hardtke s. Dtsch Med Wochenschr. 2012 Mar;137(13):640-3. doi: 10.1055/s-0031-1298980. Epub 2012 Mar 20. Dtsch Med Wochenschr. 2012. PMID: 22434171 German. No abstract available.
Ribavirin treatment of acute and chronic hepatitis E: a single-centre experience.
Pischke S, Hardtke S, Bode U, Birkner S, Chatzikyrkou C, Kauffmann W, Bara CL, Gottlieb J, Wenzel J, Manns MP, Wedemeyer H. Pischke S, et al. Among authors: hardtke s. Liver Int. 2013 May;33(5):722-6. doi: 10.1111/liv.12114. Epub 2013 Mar 13. Liver Int. 2013. PMID: 23489973 Clinical Trial.
Anti-HDV IgM as a marker of disease activity in hepatitis delta.
Wranke A, Heidrich B, Ernst S, Calle Serrano B, Caruntu FA, Curescu MG, Yalcin K, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Bremer B, Stift J, Grabowski J, Kirschner J, Port K, Cornberg M, Falk CS, Dienes HP, Hardtke S, Manns MP, Yurdaydin C, Wedemeyer H; HIDIT-2 Study Group. Wranke A, et al. Among authors: hardtke s. PLoS One. 2014 Jul 29;9(7):e101002. doi: 10.1371/journal.pone.0101002. eCollection 2014. PLoS One. 2014. PMID: 25072849 Free PMC article.
Treatment of naïve patients with chronic hepatitis C genotypes 2 and 3 with pegylated interferon alpha and ribavirin in a real world setting: relevance for the new era of DAA.
Heidrich B, Wiegand SB, Buggisch P, Hinrichsen H, Link R, Möller B, Böker KH, Teuber G, Klinker H, Zehnter E, Naumann U, Busch HW, Maasoumy B, Baum U, Hardtke S, Manns MP, Wedemeyer H, Petersen J, Cornberg M; HepNet Study Group. Heidrich B, et al. Among authors: hardtke s. PLoS One. 2014 Oct 10;9(10):e108751. doi: 10.1371/journal.pone.0108751. eCollection 2014. PLoS One. 2014. PMID: 25302676 Free PMC article.
Treatment Extension of Pegylated Interferon Alpha and Ribavirin Does Not Improve SVR in Patients with Genotypes 2/3 without Rapid Virological Response (OPTEX Trial): A Prospective, Randomized, Two-Arm, Multicentre Phase IV Clinical Trial.
Heidrich B, Cordes HJ, Klinker H, Möller B, Naumann U, Rössle M, Kraus MR, Böker KH, Roggel C, Schuchmann M, Stoehr A, Trein A, Hardtke S, Gonnermann A, Koch A, Wedemeyer H, Manns MP, Cornberg M. Heidrich B, et al. Among authors: hardtke s. PLoS One. 2015 Jun 9;10(6):e0128069. doi: 10.1371/journal.pone.0128069. eCollection 2015. PLoS One. 2015. PMID: 26057627 Free PMC article. Clinical Trial.
43 results